In the United States, Plavix(R) recovered its market standing in the third quarter, having been affected since August 8, 2006 by the launch of a generic version. Sales of the product reached $1,083 million, compared with $477 million in the third quarter of 2006. In the nine months to end September, sales of Plavix(R) were up 23.9% at $2,892 million.
In September, the FDA approved a 300mg Plavix(R) tablet that will facilitate administration of the loading dose for patients with acute coronary syndrome, as recommended (in association with aspirin) by the American College of Cardiology and the American Heart Association.
In Europe, third-quarter net sales of Plavix(R) were 6.6% higher at euro 450 million, though sales are still affected by parallel imports in Germany.
In the rest of the world, the product enjoyed robust growth of 23.8%, to euro 213 million. In Japan, the two-week limit on prescriptions imposed by the authorities was lifted in May. This accelerated the pace of growth in net sales, which reached euro 17 million for the third quarter, against euro 1 million in the third quarter of 2006. Net sales of Plavix(R) in Japan for the nine months to end September 2007 were euro 34 million, against euro 7 million in the comparable period of 2006. In October, the Japanese authorities extended the indication of Plavix(R) to patients with acute coronary syndrome (unstable angina pectoris, non-ST elevation myocardial infarction) for whom percutaneous coronary intervention (PCI) is being planned. Plavix(R) is the first drug to be approved for this indication in Japan.
Worldwide presence(1) of Aprovel(R)/ Avapro(R)/ Karvea(R)
Copyright©2007 PR Newswire.
All rights reserved